Person: DİNÇER YAZAN, CEYDA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DİNÇER YAZAN
First Name
CEYDA
Name
9 results
Search Results
Now showing 1 - 9 of 9
Publication Open Access Free and Bioavailable Vitamin D Levels of Patients with Type 1 Diabetes Mellitus and Association with Bone Metabolism(2022-06-01) DİNÇER YAZAN, CEYDA; ŞİRİKÇİ, ÖNDER; HAKLAR, GONCAGÜL; DİNÇER YAZAN C., Yaman A., HAKLAR G., ŞİRİKÇİ Ö., Deyneli O.Aim Vitamin D deficiency is known to be associated with metabolic bone diseases. The aim of this study is to evaluate vitamin D and calculated free and bioactive vitamin D levels of type 1 diabetic patients and to evaluate the association with bone turnover markers. Method This cross-sectional study includes 60 patients admitted to endocrinology outpatient clinic with diagnosis of type 1 diabetes mellitus and 60 controls. Weight, height and waist circumference were recorded and blood samples were taken for measurement of 25-hydroxyvitamin D (25(OH)D), vitamin D binding protein (VDBP), osteocalcin, bone alkaline phosphatase (bone-ALP), c-telopeptide. Free and bioavailable vitamin D levels were calculated with formula. Results Vitamin D levels of type 1 diabetic patients were significantly higher (p = 0.01). Parathormone levels of the group with vitamin D level under 20 ng/ml was significantly higher (p = 0.029). VDBP levels were similar in both groups. Correlation analysis of free and bioavailable vitamin D level with osteocalcin, c-telopeptide, bone alkaline phosphatase revealed only a weak significant correlation between free vitamin D and osteocalcin (r = -0.201; p = 0.028). A negative correlation was determined between 25(OH)D and parathormone levels (r = -0.294; p < 0.005). Serum osteocalcin, bone alkaline phosphatase and c-telopeptide levels of control group were significantly higher. Conclusion 25(OH)D levels of the study population was extremely low. The measurement of VDBP and calculated free and bioactive vitamin D levels did not show a better correlation with bone turnover markers according to 25(OH)D levels.Publication Open Access Effect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up(2022-12-01) DİNÇER YAZAN, CEYDA; BUĞDAYCI, ONUR; ILGIN, CAN; YAVUZ, DİLEK; DİNÇER YAZAN C., BUĞDAYCI O., ILGIN C., YAVUZ D.Summary Denosumab leads to improvements in BMD levels and is a well-tolerated agent according to results of randomized controlled studies but results in real-life setting are important to evaluate drug adherence and real-life efciency. In this study, we present the results of 305 patients that were treated with denosumab in our clinic. Introduction The long-term efcacy of anti-osteoclastic drugs in treatment of osteoporosis is well known. Denosumab, a novel human monoclonal antibody, is an anti-osteoclastic agent that has been shown to lead to reductions in vertebral, nonvertebral, and hip fracture risk in randomized and observational studies. Real-life data of this agent is increasing. In this study, we presented our real-life data about the 2-year follow-up of patients under denosumab treatment. Methods Osteoporotic patients who were treated with at least one denosumab injection between 2014 and 2020 years were included. Clinical and demographic data, bone turnover markers, and radiological reports (bone mineral densitometry (BMD), vertebral x-ray) were obtained from patient fles retrospectively. Results A total of 305 patients (f/m: 275/30, 68.1±11.05 years) were included. The median injection number was 4 (1–10). Two hundred seventy-three patients (89.8%) were persistent on treatment at the 12th month; 175 patients (57.3%) were persistent at 24th month. Sixty-eight patients (22%) were not using denosumab anymore, 55 of the patients were not continuing by doctor desicion and 13 were not continuing due to patient-related causes. Median BMD levels signifcantly increased from 0.809 (0.2–1.601, IQR: 0.136) to 0.861 (0.517–1.607, IQR: 0.14) in L1–L4 and from 0.702 (0.349–0.997, IQR: 0.125) to 0.745 (0.508–1.008, IQR: 0.137) in femur area at the 24th month of treatment. An improvement of 8.04% in L1–L4 BMD and 4.5% in femur neck BMD levels at the 24th month of treatment was observed. There was a signifcant decrease in bone turnover markers at the 24th month of treatment. Conclusion In our group of patients under denosumab treatment, 53% of persistence was found at 24 months and associated with improvement in BMD levels without any signifcant side efects except one case with urticarial reaction. Denosumab leads to improvements in BMD levels and is a well-tolerated agent in a real-life setting comparable to results of randomized controlled studies in patients with diferent comorbidities.Publication Metadata only Diferansiye tiroid kanserli hastalarda levotiroksin tedavisi uyum ve hedef TSH Düzeylerine ulaşma durumu: Çok merkezli çalışma(2022-05-21) YAVUZ, DİLEK; DİNÇER YAZAN, CEYDA; Yavuz D., Dinçer Yazan C.Publication Metadata only The association of free testosterone levels with coronavirus disease 2019(2022) ILGIN, CAN; Apaydin, Tugce; Sahin, Bahadır; Dashdamirova, Saida; Dincer Yazan, Ceyda; Elbasan, Onur; Ilgin, Can; Bilgin, Hüseyin; Cam, Haydar Kamil; Bahramzada, Gunel; Kucuk, Aleyna; Haklar, Goncagul; Iliksu Gozu, HulyaPublication Open Access Effect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up(2022-12-01) DİNÇER YAZAN, CEYDA; BUĞDAYCI, ONUR; ILGIN, CAN; YAVUZ, DİLEK; DİNÇER YAZAN C., BUĞDAYCI O., ILGIN C., YAVUZ D.Summary Denosumab leads to improvements in BMD levels and is a well-tolerated agent according to results of randomized controlled studies but results in real-life setting are important to evaluate drug adherence and real-life efciency. In this study, we present the results of 305 patients that were treated with denosumab in our clinic. Introduction The long-term efcacy of anti-osteoclastic drugs in treatment of osteoporosis is well known. Denosumab, a novel human monoclonal antibody, is an anti-osteoclastic agent that has been shown to lead to reductions in vertebral, nonvertebral, and hip fracture risk in randomized and observational studies. Real-life data of this agent is increasing. In this study, we presented our real-life data about the 2-year follow-up of patients under denosumab treatment. Methods Osteoporotic patients who were treated with at least one denosumab injection between 2014 and 2020 years were included. Clinical and demographic data, bone turnover markers, and radiological reports (bone mineral densitometry (BMD), vertebral x-ray) were obtained from patient fles retrospectively. Results A total of 305 patients (f/m: 275/30, 68.1±11.05 years) were included. The median injection number was 4 (1–10). Two hundred seventy-three patients (89.8%) were persistent on treatment at the 12th month; 175 patients (57.3%) were persistent at 24th month. Sixty-eight patients (22%) were not using denosumab anymore, 55 of the patients were not continuing by doctor desicion and 13 were not continuing due to patient-related causes. Median BMD levels signifcantly increased from 0.809 (0.2–1.601, IQR: 0.136) to 0.861 (0.517–1.607, IQR: 0.14) in L1–L4 and from 0.702 (0.349–0.997, IQR: 0.125) to 0.745 (0.508–1.008, IQR: 0.137) in femur area at the 24th month of treatment. An improvement of 8.04% in L1–L4 BMD and 4.5% in femur neck BMD levels at the 24th month of treatment was observed. There was a signifcant decrease in bone turnover markers at the 24th month of treatment. Conclusion In our group of patients under denosumab treatment, 53% of persistence was found at 24 months and associated with improvement in BMD levels without any signifcant side efects except one case with urticarial reaction. Denosumab leads to improvements in BMD levels and is a well-tolerated agent in a real-life setting comparable to results of randomized controlled studies in patients with diferent comorbidities.Publication Metadata only VDBP, VDR mutations and other factors related with vitamin D metabolism may be associated with type 1 diabetes mellitus(C M B ASSOC, 2018) DİNÇER YAZAN, CEYDA; Kirac, Deniz; Yazan, Ceyda Dincer; Gezmis, Hazal; Yaman, Ali; Haklar, Goncagul; Sirikci, Onder; Altunok, Elif Cigdem; Deyneli, OguzhanType 1 diabetes mellitus (T1DM) is an insulin dependent autoimmune disorder resulting the progressive destruction of pancreatic beta cells. Another possible factor considered to be related with T1DM is vitamin D deficiency. Therefore in this study it was aimed to investigate the associations between T1DM, vitamin D binding protein (VDBP) and vitamin D receptor (VDR) gene mutations which are related with vitamin D metabolism. Fifty five T1DM paitents and 40 healthy volunteers were recruited to the study. FokI (rs2228570), BsmI (rs1544410) mutations in VDR; rs4588 and rs7041 polymorphisms in VDBP were investigated with real-time polymerase chain reaction (RT-PCR). Other risk factors related with T1DM were also investigated. Results were evaluated statistically. Statistically significant relations were found in glucose, HbA1c, TSH, higher 25[ OH] D, free vitamin D, calcium, albumin, log25[ OH] D, retinopathy, higher than 30 mg/day microalbuminuria in T1DM patients. Also statistically significant association was found between C allele in Fok1 and T1DM in patients. When the relation between the risk factors and mutations were investigated, it was found that VDBP, free vitamin D and bioactive vitamin D were significantly associated with rs7041 mutation in VDBP whereas HDL was significantly associated with rs2228570 mutation in VDR. Other studies with larger data sets may demonstrate more reliable statistical results to rule out genotype-phenotype correlations of thePublication Metadata only Eri̇şki̇nli̇kte tanı alan gli̇kojen depo ti̇p-3 olgu sunumu(2022-10-20) DİNÇER YAZAN, CEYDA; TOKAY TARHAN, SENA; GÜNDÜZ, FEYZA; YAVUZ, DİLEK; Yaşar F. Z. , Dinçer Yazan C., Tokay Tarhan S., Dilber F., Yavuz D.Publication Metadata only Primer hiperparatiroidiye bağlı hiperkalsem(Akademisyen Yayınevi Kitabevi, 2024-01-01) DİNÇER YAZAN, CEYDA; YAVUZ, DİLEK; Dinçer Yazan C., Yavuz D.Publication Metadata only Vitamin d Iintoksikasyonu(Akademisyen Yayınevi Kitabevi, 2024-01-01) DİNÇER YAZAN, CEYDA; YAVUZ, DİLEK; Dinçer Yazan C., Yavuz D.